2 weeks Ago
Acelyrin, Inc. ( NASDAQ: SLRN ) Q3 2024 Earnings Call November 13, 2024 4:30 PM ET Company Participants Tyler Marciniak - Vice President, Investor Relations and Corporate Affairs Mina Kim - Chief Executive Officer Gil Labrucherie - Chief Financial Officer and Chief Business Officer Shephard Mpofu - Chief Medical Officer Conference Call Participants Tyler Van Buren - TD Cowen Emily Bodnar - H.C.
Wainwright Vikram Purohit - Morgan Stanley Samantha Semenkow - Citi Operator Good afternoon, and welcome to the Acelyrin, Inc. Third Quarter 2024 Financial Results and Company Update Conference Call. This conference call is being recorded today, November 13, 2024.
I would now like to turn the call over to Tyler Marciniak, Vice President of Investor Relations and Corporate Affairs. Tyler? Tyler Marciniak Thanks, Victor. Good afternoon, everyone, and thank you for joining us for Acelyrin’s third quarter 2024 conference call.
With me today are Mina Kim, our Chief Executive Officer; Gil Labrucherie, our Chief Financial Officer and Chief Business Officer; and Shephard Mpofu, our Chief Medical Officer. We issued a news release earlier detailing our third quarter financial results and important corporate updates. And before we begin today’s call, I’d like to remind the audience that our remarks may contain forward-looking statements such as those related to the progress of our clinical trials, our future financial operating results and investments and our ability to commercialize our product candidates.
We urge you to review the Risk Factors section of our Form 10-Q for the quarter ended September 30, 2024, which was filed today with the SEC and which is also available on our website at Acelyrin.com, along with today’s press release, which identifies certain factors that could cause our actual results, performance and events to differ materially. Finally, our statements are based on information available to us today, November 13, 2024, and we undertake no.
